The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Open accessAbstract
PURPOSE: The PRIMA study (ClinicalTrials.gov identifier: NCT00140582 ) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final PFS and overall survival (OS) results from the PRIMA study after 9 years of follow-up and provide a final overview of safety. METHODS: Patients (> 18 years of age) with previously untreated high–tumor-burden follicular lymphoma were nonrandomly assigned to receive one of three immunochemotherapy induction regimens. Responding patients were randomly assigned (stratified by induction regimen, response to induction treatment, treatment center, and geographic region) 1:1 to receive 2 years of rituximab maintenance (375 mg/m 2, once every 8 weeks), starting 8 weeks after the last induction treatment, or observation (no additional treatment). All patients in the extended follow-up provided their written informed consent (data cutoff: December 31, 2016). RESULTS: In total, 1,018 patients completed induction treatment and were randomly assigned to rituximab maintenance (n = 505) or observation (n = 513). Consent for the extended follow-up was provided by 607 patients (59.6%) of 1,018 (rituximab maintenance, n = 309; observation, n = 298). After data cutoff, median PFS was 10.5 years in the rituximab maintenance arm compared with 4.1 years in the observation arm (hazard ratio, 0.61; 95% CI, 0.52 to 0.73; P < .001). No OS difference was seen in patients randomly assigned to rituximab maintenance or observation (hazard ratio, 1.04; 95% CI, 0.77 to 1.40; P = .7948); 10-year OS estimates were approximately 80% in both study arms. No new safety signals were observed. CONCLUSION: Rituximab maintenance after induction immunochemotherapy provides a significant long-term PFS, but not OS, benefit over observation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Self-citationReport of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,461
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
Self-citationMarcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
Self-citationCasulo, C., Byrtek, M., Dawson, K. L., Zhou, X., Farber, C. M., Flowers, C. R., Hainsworth, J. D., Maurer, M. J., Cerhan, J. R., Link, B. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7534 · Cited by 850
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Self-citationMarcus, R., Imrie, K., Solal-Celigny, P., Catalano, J. V., Dmoszynska, A., Raposo, J. C., Offner, F. C., Gomez-Codina, J., Belch, A., Cunningham, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5376 · Cited by 594
Self-citationvan Oers, M. H. J., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., Jack, A., van't Veer, M., Vranovsky, A., Holte, H., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021113 · Cited by 592
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Broglio, K. R., & Berry, D. A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp369 · Cited by 491
Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H.-P., Repp, R., Wandt, H., Pott, C., Seymour, J. F., Metzner, B., Hanel, A., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016725 · Cited by 467
Self-citationNew Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma
Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M., & Miller, T. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1674 · Cited by 375
Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Grimaldi, M., & Greco, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.191 · Cited by 330
van Oers, M. H. J., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., van t Veer, M., Vranovsky, A., Holte, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5827 · Cited by 328
Hochster, H., Weller, E., Gascoyne, R. D., Habermann, T. M., Gordon, L. I., Ryan, T., Zhang, L., Colocci, N., Frankel, S., & Horning, S. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1561 · Cited by 276
Vidal, L., Gafter-Gvili, A., Leibovici, L., Dreyling, M., Ghielmini, M., Hsu Schmitz, S.-F., Cohen, A., & Shpilberg, O. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn478 · Cited by 266
Jurinovic, V., Kridel, R., Staiger, A. M., Szczepanowski, M., Horn, H., Dreyling, M. H., Rosenwald, A., Ott, G., Klapper, W., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-05-717355 · Cited by 233
Sarkozy, C., Trneny, M., Xerri, L., Wickham, N., Feugier, P., Leppa, S., Brice, P., Soubeyran, P., Gomes Da Silva, M., Mounier, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7163 · Cited by 186
Self-citationVidal, L., Gafter‐Gvili, A., Salles, G., Dreyling, M. H., Ghielmini, M. E. G., Schmitz, S. H., Pettengell, R., Witzens‐Harig, M., & Shpilberg, O. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr418 · Cited by 131
Self-citationShi, Q., Flowers, C. R., Hiddemann, W., Marcus, R. E., Herold, M. J., Hagenbeek, A., Kimby, E. K., Höchster, H. S., Vitolo, U., Peterson, B. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8651 · Cited by 120
Self-citationSeymour, J. F., Marcus, R. E., Davies, A. J., Gallop‐Evans, E., Grigg, A., Haynes, A., Herold, M. J., Illmer, T., Nilsson‐Ehle, H., Sökler, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.209015 · Cited by 112
Self-citationFollicular lymphoma: 2018 update on diagnosis and management
Freedman, A. S. (2018) · American Journal of Hematology · doi:10.1002/ajh.24937 · Cited by 110
Shi, Q., Schmitz, N., Ou, F., Dixon, J. G., Cunningham, D., Pfreundschuh, M. G., Seymour, J. F., Jaeger, U., Habermann, T. M., Haïoun, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9124 · Cited by 105
Self-citationCiani, O., Davis, S., Tappenden, P., Garside, R., Stein, K., Cantrell, A. J., Saad, E. D., Buyse, M. E., & Taylor, R. S. (2014) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462314000300 · Cited by 87
Salles, G., Seymour, J. F., Feugier, P., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2013) · Blood · doi:10.1182/blood.v122.21.509.509 · Cited by 83
Self-citation
Cited by
Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00335-7 · Cited by 461
Dreyling, M., Ghielmini, M., Rule, S., Salles, G., Ladetto, M., Tonino, S. H., Herfarth, K., Seymour, J. F., & Jerkeman, M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.008 · Cited by 270
Self-citationThe Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117
Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., et al. (2025) · Blood · doi:10.1182/blood.2024025454 · Cited by 94
Metadata
- Authors
- Bachy, E., Seymour, J. F., Feugier, P., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Catalano, J. V., Brice, P., Lemonnier, F., Martin, A., Casasnovas, O., Pedersen, L. M., Dorvaux, V., Simpson, D., Leppa, S., Gabarre, J., da Silva, M. G., Glaisner, S., Ysebaert, L., Vekhoff, A., Intragumtornchai, T., Le Gouill, S., Lister, A., Estell, J. A., Milone, G., Sonet, A., Farhi, J., Zeuner, H., Tilly, H., & Salles, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-11-01
- Volume
- 37
- Issue
- 31
- Pages
- 2815-2824
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2963759094
- Cited by
- 290
- References
- 29
- FWCI
- 21.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.